200 related articles for article (PubMed ID: 29111751)
1. Extraordinary Long-Term-Stability in Kinetically Stabilized Amorphous Solid Dispersions of Fenofibrate.
Theil F; Milsmann J; Kyeremateng SO; Anantharaman S; Rosenberg J; van Lishaut H
Mol Pharm; 2017 Dec; 14(12):4636-4647. PubMed ID: 29111751
[TBL] [Abstract][Full Text] [Related]
2. Frozen in Time: Kinetically Stabilized Amorphous Solid Dispersions of Nifedipine Stable after a Quarter Century of Storage.
Theil F; Anantharaman S; Kyeremateng SO; van Lishaut H; Dreis-Kühne SH; Rosenberg J; Mägerlein M; Woehrle GH
Mol Pharm; 2017 Jan; 14(1):183-192. PubMed ID: 28043131
[TBL] [Abstract][Full Text] [Related]
3. Crystallization Risk Assessment of Amorphous Solid Dispersions by Physical Shelf-Life Modeling: A Practical Approach.
Liu B; Theil F; Lehmkemper K; Gessner D; Li Y; van Lishaut H
Mol Pharm; 2021 Jun; 18(6):2428-2437. PubMed ID: 34032433
[TBL] [Abstract][Full Text] [Related]
4. Investigating the effect of moisture protection on solid-state stability and dissolution of fenofibrate and ketoconazole solid dispersions using PXRD, HSDSC and Raman microscopy.
Kanaujia P; Lau G; Ng WK; Widjaja E; Schreyer M; Hanefeld A; Fischbach M; Saal C; Maio M; Tan RB
Drug Dev Ind Pharm; 2011 Sep; 37(9):1026-35. PubMed ID: 21417604
[TBL] [Abstract][Full Text] [Related]
5. Manufacturing Amorphous Solid Dispersions with a Tailored Amount of Crystallized API for Biopharmaceutical Testing.
Theil F; Milsmann J; Anantharaman S; van Lishaut H
Mol Pharm; 2018 May; 15(5):1870-1877. PubMed ID: 29648833
[TBL] [Abstract][Full Text] [Related]
6. Evaluation of the recrystallization kinetics of hot-melt extruded polymeric solid dispersions using an improved Avrami equation.
Feng X; Ye X; Park JB; Lu W; Morott J; Beissner B; Lian ZJ; Pinto E; Bi V; Porter S; Durig T; Majumdar S; Repka MA
Drug Dev Ind Pharm; 2015; 41(9):1479-87. PubMed ID: 25224341
[TBL] [Abstract][Full Text] [Related]
7. Characterization of Amorphous Solid Dispersions and Identification of Low Levels of Crystallinity by Transmission Electron Microscopy.
S'ari M; Blade H; Cosgrove S; Drummond-Brydson R; Hondow N; Hughes LP; Brown A
Mol Pharm; 2021 May; 18(5):1905-1919. PubMed ID: 33797925
[TBL] [Abstract][Full Text] [Related]
8. Accelerated stability modeling of recrystallization from amorphous solid Dispersions: A Griseofulvin/HPMC-AS case study.
Leon AS; Waterman KC; Wang G; Wang L; Cai T; Zhang X
Int J Pharm; 2024 May; 657():124189. PubMed ID: 38701906
[TBL] [Abstract][Full Text] [Related]
9. Amorphous Sulfadoxine: A Physical Stability and Crystallization Kinetics Study.
Aucamp M; Milne M; Liebenberg W
AAPS PharmSciTech; 2016 Oct; 17(5):1100-9. PubMed ID: 26531745
[TBL] [Abstract][Full Text] [Related]
10. Second harmonic generation microscopy as a tool for the early detection of crystallization in spray dried dispersions.
Correa-Soto C; Trasi NS; Schmitt PD; Su Y; Liu Z; Miller E; Variankaval N; Marsac PJ; Simpson GJ; Taylor LS
J Pharm Biomed Anal; 2017 Nov; 146():86-95. PubMed ID: 28866472
[TBL] [Abstract][Full Text] [Related]
11. Comparative studies on physicochemical stability of cyclosporine A-loaded amorphous solid dispersions.
Sato H; Kawabata Y; Yuminoki K; Hashimoto N; Yamauchi Y; Ogawa K; Mizumoto T; Yamada S; Onoue S
Int J Pharm; 2012 Apr; 426(1-2):302-306. PubMed ID: 22285473
[TBL] [Abstract][Full Text] [Related]
12. Quantitative Measures of Crystalline Fenofibrate in Amorphous Solid Dispersion Formulations by X-Ray Microscopy.
Neilly JP; Yin L; Leonard SE; Kenis PJA; Danzer GD; Pawate AS
J Pharm Sci; 2020 Oct; 109(10):3078-3085. PubMed ID: 32679216
[TBL] [Abstract][Full Text] [Related]
13. Characterization of Phase Separation Propensity for Amorphous Spray Dried Dispersions.
McNamara D; Yin S; Pan D; Crull G; Timmins P; Vig B
Mol Pharm; 2017 Feb; 14(2):377-385. PubMed ID: 28068097
[TBL] [Abstract][Full Text] [Related]
14. Comparison of Differential Scanning Calorimetry, Powder X-ray Diffraction, and Solid-state Nuclear Magnetic Resonance Spectroscopy for Measuring Crystallinity in Amorphous Solid Dispersions - Application to Drug-in-polymer Solubility.
Jarrells TW; Munson EJ
J Pharm Sci; 2022 Oct; 111(10):2765-2778. PubMed ID: 35421430
[TBL] [Abstract][Full Text] [Related]
15. Physical stability and recrystallization kinetics of amorphous ibipinabant drug product by fourier transform raman spectroscopy.
Sinclair W; Leane M; Clarke G; Dennis A; Tobyn M; Timmins P
J Pharm Sci; 2011 Nov; 100(11):4687-99. PubMed ID: 21681752
[TBL] [Abstract][Full Text] [Related]
16. An improved kinetics approach to describe the physical stability of amorphous solid dispersions.
Yang J; Grey K; Doney J
Int J Pharm; 2010 Jan; 384(1-2):24-31. PubMed ID: 19786081
[TBL] [Abstract][Full Text] [Related]
17. Unravelling the relationship between degree of disorder and the dissolution behavior of milled glibenclamide.
Mah PT; Laaksonen T; Rades T; Aaltonen J; Peltonen L; Strachan CJ
Mol Pharm; 2014 Jan; 11(1):234-42. PubMed ID: 24224572
[TBL] [Abstract][Full Text] [Related]
18. A Mechanistic Model for Predicting the Physical Stability of Amorphous Solid Dispersions.
Ojo AT; Lee PI
J Pharm Sci; 2021 Apr; 110(4):1495-1512. PubMed ID: 32818440
[TBL] [Abstract][Full Text] [Related]
19. The Development of Quasi-isothermal Calorimetry for the Measurement of Drug-Polymer Miscibility and Crystallization Kinetics: Olanzapine-Loaded PLGA Microparticles.
Askin S; Zhao M; Gonçalves AD; Gaisford S; Craig DQM
Mol Pharm; 2018 Aug; 15(8):3332-3342. PubMed ID: 29933697
[TBL] [Abstract][Full Text] [Related]
20. Amorphous solid dispersions of piroxicam and Soluplus(®): Qualitative and quantitative analysis of piroxicam recrystallization during storage.
Lust A; Strachan CJ; Veski P; Aaltonen J; Heinämäki J; Yliruusi J; Kogermann K
Int J Pharm; 2015; 486(1-2):306-14. PubMed ID: 25843761
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
